ES2829254T3

Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Abstract

A compound of formula IB: ** (See formula) ** or a pharmaceutically acceptable salt, solvate, enantiomer, diastereoisomer, racemate or mixture thereof, wherein: A is: ** (See formula) ** X1 is -CR11R12- or -OCH2CH2-, wherein the oxygen atom is distal to the RIB moiety in A; R11 and R12 are independently hydrogen or C1-C4 alkyl, wherein the alkyl is optionally substituted with one or more of halogen, -OH, -SH, or -NH2; X2 is absent, it is -O-, -C (O) O-, or -OCH2-, wherein the oxygen atom is distal to the RIB moiety in A; each RIB is independently hydrogen, -C1-C6 alkyl, ** (See formula) ** or RIB is an amino acid residue attached via the carbonyl group, wherein the alkyl is optionally substituted with one or more halogen, -OH, -SH or -NH2; v is 0 or 1; n is 0, 1, 2 or 3 and when X2 is -C (O) O-, n is 0; p is 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11; q is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18; Rz is hydrogen, halogen, -C1-C4 alkylthio, -C1-C4 alkoxy, -C1-C4 alkyl, -C2-C4 alkenyl, -C2-C4 alkynyl, aryl, heteroaryl, -C3-C8 cycloalkyl, -C4-cycloalkenyl C8 or 3- to 5-membered non-aromatic heterocycle, wherein each alkylthio, alkoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocycle is optionally substituted with one or more of halogen, -OH, -SH, or -NH2; Ra, Rb, Rx, and Ry are each independently selected from the group consisting of hydrogen, halogen, -OH, -SH, -C1-C6 alkoxy, aryloxy, -C1-C6 alkylthio, arylthio, -OC (O) C1 alkyl -C6, -OC (O) aryl, -C1-C6 alkyl, -C2-C6 alkenyl, -25 C2-C6 alkynyl, aryl, heteroaryl, -C3-C8 cycloalkyl, and -C4-C8 cycloalkenyl, wherein each alkoxy , aryloxy, alkylthio, arylthio, alkyl, aryl, alkenyl, alkynyl, heteroaryl, cycloalkyl or cycloalkenyl is optionally substituted with one or more of halogen, -OH, -SH or -NH2; or any two Ra or Rb, together with the atom to which they are both attached, may combine to form a C3-C8 spirocycloalkyl or 3- to 8-membered spiroheterocycle; or any two Ra or Rb, when on adjacent atoms, can combine to form a carbon-carbon double bond or a cis or trans carbon-carbon triple bond; or any two Ra or Rb, when on adjacent atoms, may combine to form an aryl, heteroaryl, -C3-C10 -cycloalkyl, -C4-C10 -cycloalkenyl, or 5- to 10-membered ring-membered heterocycle; or any CRaRb can be replaced by -O-, -S-, -S (O) - or -SO2-; or any two Rx or Ry, together with the atom to which they are both attached, may combine to form a 3- to 8-membered - spirocycloalkyl or spiroheterocycle; or any two Rx or Ry, when on adjacent atoms, can combine to form a carbon-carbon double bond or a cis or trans carbon-carbon triple bond; or any two Rx or Ry, when on adjacent atoms, may combine to form an aryl, heteroaryl, -C3-C10 -cycloalkyl, -C4-C10 -cycloalkenyl, or 5- to 10-membered ring-membered heterocycle; or any CRxRy can be replaced by -O-, -S-, -S (O) - or -SO2-; R1 and R45 are each independently hydrogen, halogen, -N3, -OH, -NH2, -SH, -C1-C6 alkyl, -C3-C6 cycloalkyl, -C2-C6 alkenyl, -C4-C8 cycloalkenyl, -C2 alkynyl -C6, -C8-C12 cycloalkynyl, -C 1-6 alkoxy or -C 1-6 alkylthio in which each alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkoxy or alkylthio is independently substituted with one or more halogen, - N3, -OH, -NH2 or -SH; R2, R3, R4, and R44 are each independently hydrogen, halogen, -N3, -OH, -NH2, -SH, -C1-C6 alkyl, -C1-C6 alkoxy, or -C1-C6 alkylthio, wherein each alkyl , alkoxy or alkylthio is optionally substituted with one or more of halogen, -N3, -OH, -NH2 or -SH; or R3 and one of R4 and R44, together with the atoms to which they are attached may form a carbon-carbon double bond; R5 is independently hydrogen, -RIB, M +, aryl, aralkyl, -C1-C6 alkyl, -C1-C6 heteroalkyl, cycloalkyl, non-aromatic heterocyclic ring or heteroaryl, wherein M + is a cation and wherein each aryl, aralkyl , alkyl, heteroalkyl, cycloalkyl, heterocycle, or heteroaryl is optionally substituted with one or more of halogen, -N3, -OH, -NH2, or -SH, and wherein R5 is not an amino acid; and Rc is -C1-C6 alkyl, -C3-C6 cycloalkyl, -C2-C6 alkenyl, -C4-C8 cycloalkenyl, -C2-C6 alkynyl, -C8-C12 cycloalkynyl or aryl, wherein each alkyl, cycloalkyl, alkenyl , cycloalkenyl or aryl is optionally substituted with one or more of halogen, -N3, -OH, -NH2 or -SH.

Term

9.9 yearsto projected expiry

Projected expiry 8 August 2036, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

27 members in 14 offices

This recordMember, by publication datePriority claim4 more offices are in the list below

Priority claims5

Priority claims
DocumentOfficeKindDate
201562202010United States of AmericaP
201562202010PUnited States of America
201606645United KingdomA
201606645United Kingdom
2016046056United States of AmericaW

Members27

Family members, oldest first
DocumentOfficeKind
CA2992278A1CanadaA1
WO2017024310A1World Intellectual Property Organization (WIPO)A1
US2017044202A1United States of AmericaA1
US2017137454A1United States of AmericaA1
US9701706B2United States of AmericaB2
US9708359B2United States of AmericaB2
US2017253628A1United States of AmericaA1
AU2016301188A1AustraliaA1
IL257122AIsraelA
IL257122D0IsraelD0
KR20180039666ARepublic of KoreaA
CN108026136AChinaA
MX2018001073AMexicoA
EP3331895A1European Patent Office (EPO)A1
EA201890454A1Eurasian Patent Organization (EAPO)A1
PH12018500263A1PhilippinesA1
JP2018523665AJapanA
BR112018002399A2BrazilA2
US10407457B2United States of AmericaB2
US2020199167A1United States of AmericaA1
EP3331895B1European Patent Office (EPO)B1
US10941175B2United States of AmericaB2
ES2829254T3This recordSpainT3
US2022002335A1United States of AmericaA1
KR102630013B1Republic of KoreaB1
US11981700B2United States of AmericaB2
US2025084119A1United States of AmericaA1